Rabbitturd getting chased around the briar patch this

New Post Public Reply Private Reply Replies (2) Message Board
scgmck1
253
Rabbitturd getting chased around the briar patch this afternoon. Here's a copy of a post from Daubers UP at the swamp for those who don't have the stomach to look at the bullshit over there. A few other nice jabs by others too.
And let's not forget that the Cocks are in action tonight against the Baylor Bears in the Sweet 16 matchup at Madison Square Garden. Tipoff scheduled at 7:19.
GO GAMECOCKS!!!!


DaubersUP Friday, 03/24/17 01:38:28 PM
Re: TheBunny post# 176226
Post # of 176244

Bunny what happened to this kind of excitement?
____________________________________________
TheBunny Monday, 11/05/12 08:51:14 AM
Re: NotRichYet2 post# 10542
Post #
10545
of 176230 Go
>>HOW CAN A STOCK WITH A CURE FOR 50% of all cancers be selling at 92 cents ?<<

I know this questions is directed to Bioman but my take; If it wasn't for all the micro scammers in the last few years promising that they got the cure for the world, then just diluting their stockholders to near zero so a few insiders can 'Live Large', we would normally be about $3.50 range at this stage with all things considered.
Also the clobbering in 2008 got many to shun away as many unloaded at the bottom never to come back.

Investors been stung on so many of these 'Cure-all's that are 'just around the corner'. I have been. Ask any veteran mini-bio investor.
CTIX is so different and such a pleasure and welcome change to the others out there. Here we have a CEO that answer questions and gives as many details as he can to his stockholders. Other places when for months stockholders ask management 'Where is TOX?', it just goes unanswered.

I do believe we will see a healthy adjustment in share price when dosing PR is released and more so when results are published.
Investors want to see a bit more now-a-days before dipping in.
However they will miss the rapid growth if test results are outstanding but that's the trade off. As I have said before; Investor nature in some is such that they are more willing to buy something at $4.00 as that number seems to have 'value' and it's 'growing', rather than take the same set of circumstances in a pipeline and it's a $1.00, well hey, there not much value there...'hovering too close to the ground'. Lot of it is psychological. Topic for another day.

Watch how many start coming on here when we are over $2.00. Then when we get uplisted.
But now, the great unwashed feeling a bit unsure about Uncle Billy's recommendation will ask their broker for their opinion. What do you think the broker will say when they know zip about CTIX, and they would prefer to sell them something where he gets a extra 'back-door' commish ?


-bunny-

_______________________________________________________
In late 2012 CTIX had about 93 Million OS - and was just about to dose the first patient in the K phase 1 trial.

So no active trials yet. Here is the PR for the first patient being recruited and enrolled about - 3 days after your post above.

http://www.cellceutix.com/press-release/2016/...-hospitals

http://www.cellceutix.com/press-release/2016/...g-kevetrin

_______________________________________

You were so excited about Leo and CTIX and they did not even have one HUMAN clinical trial dosing??? They only had a dream of Prurisol and were just about start dosing K. So now look at your attitude. I can actually see when you turned looking back - post by post.

So you were screaming this should have been in the 3.50 range back then with zero human clinical results and only 2 drugs on the pipeline....

Fast forward 4-5 years and we added Brilacidin and completed SEVERAL major HUMAN clinical trials with STELLAR results and you are now screaming this should be .60? Hmmmmmmmmmmmmmmmmmm?

And better yet - CTIX did all of this with only diluting 30 million shares? That is 30 million shares to buy a potential multi-billion or multi-blockbuster compound (B) and the entire platform, took K through a multi year successful phase 1, started a phase 2 Ovarian trial, completed a couple Prurisol trials and currently in a 2B showing much promise, have B Absssi phase 3 chilling with dominant data comparing it to Dapto from CTIX's phase 2B, OM phase 2 about to deliver interim results, PoC phase 2 UP/UPS onto the final cohort with excellent data thus far, and the list goes on......

So if 3.50 was your price back in late 2012 with zero clinical trials to boot and only P and K! What do you really value CTIX at now?


TIA
Daub

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Lord, help me to be the person that my dogs think I am...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CopperWood Senior Living Revives Historic Campus

Updated Category News Views 11

A Fresh Start for Peapack-Gladstone's Corporate Relic Dust off the pages of history—Peapack-Gladstone's old Pfizer/Beneficial Finance campus is getting a makeover, and boy, it’s not your run-of-the-mill renovation. We're talking adaptive reuse to the tune of nearly $200 million, morphing this architectural gem into CopperWood Senior Living. With all the office...

Continue Reading
Ashling's New Feat: Microsoft Recognition in AI

Updated Category News Views 18

Microsoft's Stamp of Approval for Ashling Ah, recognition—it's not just for egos. When Ashling, an AI consultancy heavyweight, gets a nod from Microsoft, it's worth more than a footnote in the company newsletter. This isn't some participation trophy. Nope, it's a badge saying they know their Data & AI, and Digital & App Innovation inside out. On October 29, 2026,...

Continue Reading
ESENTIA Lifts EBITDA, Reduces Debt, Eyes Expansion

Updated Category News Views 85

ESENTIA Flexes Financial Muscles: What's the Deal? Walk with me through the gritty world of financials, and you’ll see that ESENTIA’s latest figures are a mixed bag with a tantalizing upside. We're talking about adjusted EBITDA ticking up to a cool $86 million in the third quarter of '26, a 1.3% lift from last year. Not too shabby, eh? Especially when you're grappling...

Continue Reading
Digital Art Sparks Future City Visions in Beijing

Updated Category News Views 8

Beijing's Bold Digital Art Venture: A New Era in Creativity Ever felt the jittery buzz of innovation on the cutting edge? That's exactly what visitors experienced in Beijing's 'Spiritual Land: Future World of Inspiration' exhibition at the BOE Yiyun Digital Art Center. Set against the backdrop of the sprawling metropolis, this joint effort between Beijing and Linz aims to...

Continue Reading
XREAL AURA: A New Era of Wired XR Glasses

Updated Category News Views 60

Pioneering the XR Frontier Welcome to another day under the sun of cutting-edge tech, where XREAL's striking a chord with its new wired XR glasses—AURA. First off, don't let the tangled history of tech hype get to you. In the wild world of extended reality, we've seen plenty of flash, not enough substance. But XREAL's hitting the market with AURA, and I gotta say,...

Continue Reading
Hershey's Sweet Results: 2026 Earnings Soar

Updated Category News Views 75

Hershey's 2026 Q3 Financial Performance: A Closer Look At the end of September, The Hershey Company (NYSE: HSY) dished out some eye-popping numbers for their third quarter. With a net sales increase of 3.0%, they clocked in at $3,275.5 million. More importantly, earnings per share-diluted shot up by a whopping 111.8%, landing at $2.88. Clearly, Hershey’s strategic moves...

Continue Reading
Torchy's Tacos Reintroduces Nookies: Fan Favorite Returns

Updated Category News Views 0

A Sweet Return to the Menu In the wild world of fast-casual dining, bringing back a beloved menu item is like striking gold. Torchy's Tacos is doing just that by reintroducing their legendary Nookies—fried chocolate chip cookie dough bites that have been a crowd favorite since 2008. After a two-year hiatus, these treats are back, complete with a cinnamon-sugar twist to...

Continue Reading
DayOne's Bold Energy Moves With Sembcorp for Asia Growth

Updated Category News Views 79

It seems the digital world and power supply have locked in a new dance as DayOne Data Centers teams up with Sembcorp Utilities. It's high time we gave this story a solid look, especially with data centers gobbling energy faster than my old trading partner downs an espresso. Tackling Energy Constraints Head-On The digital infrastructure beast is hungry for power, and...

Continue Reading
Direxion Targets Anthropic's IPO with Bold New ETFs

Updated Category News Views 17

Anthropic's IPO Sparks Direxion's Latest ETF Moves Alright, folks, Anthropic's public filing for an IPO isn't just turning heads—it's lighting up the trading floor! Following this buzz, Direxion grabs its chance to unleash two new ETFs designed to seize on Anthropic's rollercoaster debut. We're talking about the Direxion Daily Anthropic Bull 2X ETF (ANTO) and the...

Continue Reading
GARDANT Expands Reach with International Partnership

Updated Category News Views 0

GARDANT Global's Strategic Expansion Well, today we saw GARDANT Global make a move that screams ambition. They’re hooking up with International Offset Corporation (IOC) to muscle up their game in the murky waters of government procurement. Why does this matter? Because it's all about who gets the contracts, and with GARDANT’s newfound reach, they’re not just...

Continue Reading

Top 5 Most Recently Viewed Articles

Marex Group Faces Class Action Lawsuit Amid Serious Allegations

Updated Category News Views 293

Marex Group In the Spotlight The Marex Group, operating under the ticker symbol MRX, has recently come under scrutiny due to allegations of serious misconduct. Investors who have incurred significant losses are now facing the deadline to file lead plaintiff applications regarding a class action lawsuit. Key Details of the Class Action Marex Group plc, prominently...

Continue Reading
Genesis Shines Bright with Platinum Award for CSR Initiatives

Updated Category News Views 160

Genesis Shines Bright with Platinum Award for CSR Initiatives Genesis has recently been recognized for its outstanding corporate social responsibility efforts, particularly its mini-pitch initiative in collaboration with U.S. Soccer Foundation. This remarkable achievement showcases the company's unwavering commitment to empowering youth and fostering community engagement....

Continue Reading
Protext Mobility Expands Advisory Board with Key Leaders

Updated Category News Views 122

Protext Mobility Strengthens Advisory Board to Drive Growth Protext Mobility, Inc. (OTC: TXTM), a forward-thinking player in the biotechnology and alternative wellness space, has recently expanded its Advisory Board. This strategic decision comes as part of their ongoing commitment to innovation and transparency in operations. Formation of the Advisory Board Launched just...

Continue Reading
Avista Corp. Announces Q4 Earnings Call for 2024 Results

Updated Category News Views 101

Avista Corp. to Host Fourth Quarter 2024 Earnings Call Avista Corp. is set to share insights regarding their fourth quarter results for 2024 through a conference call and webcast. Scheduled for an early morning session on a Wednesday, this opportunity will allow stakeholders to engage directly with the company's financial updates and key operational highlights. Details of...

Continue Reading
Frontline plc Announces Q2 2024 Presentation Details

Updated Category News Views 112

Frontline plc's Second Quarter 2024 Presentation Frontline plc is set to announce its results for the second quarter of 2024. This eagerly awaited presentation will be held via webcast and conference call, providing investors and stakeholders with essential insights into the company's recent performance. Key Information About the Presentation The upcoming presentation...

Continue Reading